Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer

[1]  H. Yoshida,et al.  Real‐world data on NGS using the Oncomine DxTT for detecting genetic alterations in non‐small‐cell lung cancer: WJOG13019L , 2021, Cancer science.

[2]  Y. Yatabe,et al.  An alert to possible false positives with a commercial assay for METex14 skipping. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  Kenji Suzuki,et al.  Histological characteristics of lung adenocarcinoma with uncommon actionable alterations: special emphasis on MET exon 14 skipping alterations , 2020, Histopathology.

[4]  M. Masuda,et al.  Tissue surface area and tumor cell count affect the success rate of the Oncomine Dx Target Test in the analysis of biopsy tissue samples , 2020, Thoracic cancer.

[5]  H. Groen,et al.  Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. , 2020, The New England journal of medicine.

[6]  E. Feuer,et al.  The Effect of Advances in Lung-Cancer Treatment on Population Mortality. , 2020, The New England journal of medicine.

[7]  Mengzhao Wang,et al.  MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis , 2020, OncoTargets and therapy.

[8]  S. Digumarthy,et al.  Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations , 2019, Cancers.

[9]  H. Aburatani,et al.  Small lung tumor biopsy samples are feasible for high quality targeted next generation sequencing , 2019, Cancer science.

[10]  Junjie Zhu,et al.  EGFR mutations are significantly associated with visceral pleural invasion development in non-small-cell lung cancer patients , 2019, Cancer management and research.

[11]  Jie Yang,et al.  Tepotinib in Non‐Small Cell Lung Cancer with MET Exon 14‐Skipping Mutations or MET Amplification: a Phase 2 Trial in Progress: OA06 , 2018, The New England journal of medicine.

[12]  Wen Zhang,et al.  Correlation between EML4-ALK, EGFR and clinicopathological features based on IASLC/ATS/ERS classification of lung adenocarcinoma , 2018, Medicine.

[13]  H. Saya,et al.  Prospects for new lung cancer treatments that target EMT signaling , 2018, Developmental dynamics : an official publication of the American Association of Anatomists.

[14]  Min Zhang,et al.  HGF induces EMT in non-small-cell lung cancer through the hBVR pathway. , 2017, European journal of pharmacology.

[15]  D. Cohen,et al.  Publisher's Note , 2017, Neuroscience & Biobehavioral Reviews.

[16]  Yan-Ze Jin,et al.  MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status , 2016, Oncotarget.

[17]  Matthew B Schabath,et al.  Clinical and CT characteristics of surgically resected lung adenocarcinomas harboring ALK rearrangements or EGFR mutations. , 2016, European journal of radiology.

[18]  P. Stephens,et al.  Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  Y. Yatabe,et al.  Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma , 2016, PloS one.

[20]  Kunihiko Kobayashi,et al.  CT Features of Epidermal Growth Factor Receptor–Mutated Adenocarcinoma of the Lung: Comparison with Nonmutated Adenocarcinoma , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  Ying Liu,et al.  CT Features Associated with Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma. , 2016, Radiology.

[22]  T. Mok,et al.  MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non–Small Cell Lung Carcinoma with Poor Prognosis , 2016, Clinical Cancer Research.

[23]  Tae Jung Kim,et al.  Radiologic Characteristics of Surgically Resected Non-Small Cell Lung Cancer With ALK Rearrangement or EGFR Mutations. , 2016, The Annals of thoracic surgery.

[24]  Junichi Shimizu,et al.  Anaplastic lymphoma kinase gene rearrangements in patients with advanced-stage non-small-cell lung cancer: CT characteristics and response to chemotherapy , 2013, Cancer medicine.

[25]  Robert Brian Jenkins,et al.  Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  G. Giaccone,et al.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. , 2013, Archives of pathology & laboratory medicine.

[27]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[28]  Young Hak Kim,et al.  Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma , 2011, Cancer.

[29]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[30]  J. Minna,et al.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[31]  M. Chung,et al.  CT findings of surgically resected pleomorphic carcinoma of the lung in 30 patients. , 2005, AJR. American journal of roentgenology.

[32]  A. Drilon,et al.  Targeting MET in Lung Cancer: Will Expectations Finally Be MET? , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[33]  Massimo Bellomi,et al.  CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer , 2015, European Radiology.

[34]  Hodgkin Lymphoma.  NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines , 2014 .